Torrey Pines Law GroupFree Consultation
≡
  • About Us
    • About Our Firm
    • The Advantages of Hiring Our Firm
    • Recent Successes
    • Client Testimonials
    • Careers
    • Diversity, Equity & Inclusion
    • Locations
    • Boston
      • Boston Patent Atorneys
      • Boston FDA Regulatory Counsel
      • Boston Technology Transactions
    • Irvine
      • Irvine Patent Atorneys
      • Irvine FDA Regulatory Counsel
      • Irvine Technology Transactions
    • Los Angeles
      • Los Angeles Patent Atorneys
      • Los Angeles FDA Regulatory Counsel
      • Los Angeles Technology Transactions
    • San Diego
      • San Diego Patent Atorneys
      • San Diego FDA Regulatory Counsel
      • San Diego Technology Transactions
    • Contact
  • Professionals
    • Meet Our Team
    • Randy Berholtz, MLitt, MBA, JD
    • Robert Buchanan, PhD, JD
    • Kevin Buckley, JD
    • Frank Chen, PhD
    • Doranne Frano, MS, MBA
    • Dmitry Kryndushkin, PhD
    • Mark Malek, JD
    • James McFarland, JD
    • Eleanor Musick, JD
    • Shihong Nicolaou, PhD
    • Steven Stupp, PhD
    • Kyle Welch, JD
    • Fawn Zhang, PharmD, JD
    •  
    • Administration
    • Jaenna Barnard
    • Carina Collins
    • Amy Stedman
    • Cyndi Willis
    •  
    • Foreign Associates
  • Intellectual Property
    • Comprehensive IP Protection
    • Patent Preparation & Prosecution
    • ● Artificial Intelligence Patents
    • ● Biotechnology Patents
    • ● Chemistry Patents
    • ● Convergence Technology Patents
    • ● In Vitro Diagnostics Patents
    • ● Lasers & Optics Patents
    • ● Medical Device Patents
    • ● Pharmaceutical Patents
    • ● Pharmaceutical Lifecycle Management
    • ● Semiconductor Patents
    • ● Software Patents
    • ● Telecommunications Patents
    • ● Telemedicine Patents
    • National Phase Entry (PCT)
    • IP Litigation
    • IP Opinions & Counseling
    • IP Resources
      • Patent Rights Overview
      • International Patent Law
      • U.S. Patent Law
        • Patent Eligibility
        • Novelty
        • Obviousness
        • Written Description
        • Enablement
      • Anatomy of a U.S. Patent
        • Utility Patent
        • Design Patent
        • Plant Patent
      • Trademark Law
      • Copyright Law
      • Trade Secrets
      • Know How
      • Intangible Assets
  • Tech Transactions
    • International Technology Transactions
    • Corporate Strategy
    • Business Agreements
    • Transactional Due Diligence
    • Intellectual Property Agreements
    • Intellectual Property Due Diligence
    • Regulatory Agreements
    • Regulatory Due Diligence
  • FDA Regulatory
    • Global Strategic Counseling
    • Dossier Submissions
    • Quality Compliance (ISO)
    • CE Mark - MDR Services
    • Digital Health
    • Hatch-Waxman & Biosimilars
    • Labeling, Advertising & Promotion
    • Reimbursement & Health Economics
  • Experience
    • Our International Experience
    • Multinational Companies
    • Public Companies
    • Private Companies
    • Research & Academic Institutions
    • Hospitals & Physicians
    • Startups & Entrepreneurs
  • Contact
background
Hide
 
Show
  • background
  • torrey-pines-broken-hill
  • torrey-pines-sunset

Patent Written Description

Patent Written Description

Adequately Describing an Invention

The written description requirement requires a patent applicant to be in possession of the specific subject matter claimed as of the filing date of the patent application. Possession is shown by describing the invention, with all its claimed limitations. Although the applicant does not have to describe exactly the subject matter claimed, the description must clearly allow persons skilled in the art to recognize that the applicant(s) invented what is claimed. A description of what a material does, rather than what it is, usually is not sufficient.

All claims are subject to the written description requirement, including:

  • Original claims
  • New claims and amended claims
  • Claims asserting benefit of an earlier priority or filing date

Each claim limitation must be expressly, implicitly, or inherently supported in the originally filed disclosure. Each claim must include all elements which applicant has described as essential or critical.

The Written Description Requirement is satisfied by the disclosure of such descriptive means as:

  • Formulas
  • Words
  • Structures
  • Figures
  • Diagrams
  • Functional characteristics when coupled with a known or disclosed correlation between function and structure

that fully set forth the claimed invention.

The scope of claims are examined as a whole giving the broadest reasonable interpretation in light of and consistent with the description. Factors considered when analyzing claims for compliance with the written description requirement include:

  1. Actual reduction to practice:

    Does the specification show any embodiments that meet all the limitations of the claim reduced to practice? Note that reduction to practice is not required to meet the written description requirement.

  2. Disclosure of drawings or structural chemical formulas:

    An applicant may show possession of an invention by disclosure of drawings or structural chemical formulas that are sufficiently detailed to show that applicant was in possession of the claimed invention as a whole.

  3. Sufficient relevant identifying characteristics:
    1. Complete structure
    2. Partial structure
    3. Physical and/or chemical properties
    4. Functional characteristics when coupled with correlation between structure and function
  4. Method of making the claimed invention.
  5. Level of skill and knowledge in the art.

    What is conventional or well known to one skilled in the art need not be disclosed in detail

  6. Predictability of the art.

A written description determination for genus claims (broad claims which cover more specific claims) includes analyzing whether the inventor was in possession of each claim drawn to a single embodiment or species first, and then for each claim drawn to a genus. Written description for a claimed genus may be satisfied through sufficient description of a representative number of species:

  1. by showing an inverse function of the skill and knowledge in the art
  2. by showing whether one of skill in the art would recognize necessary common attributes or features possessed by the members of the genus
  3. in an unpredictable art, adequate written description of a genus which embraces widely variant species cannot be achieved by disclosing only one species within the genus
≡
  • Comprehensive IP Protection
  • Patent Preparation & Prosecution
  • ● Artificial Intelligence Patents
  • ● Biotechnology Patents
  • ● Chemistry Patents
  • ● Convergence Technology Patents
  • ● In Vitro Diagnostics Patents
  • ● Lasers & Optics Patents
  • ● Medical Device Patents
  • ● Pharmaceutical Patents
  • ● Pharmaceutical Lifecycle Management
  • ● Semiconductor Patents
  • ● Software Patents
  • ● Telecommunications Patents
  • ● Telemedicine Patents
  • National Phase Entry (PCT)
  • IP Litigation
  • IP Opinions & Counseling
  • IP Resources
    • Patent Rights Overview
    • International Patent Law
    • U.S. Patent Law
      • Patent Eligibility
      • Novelty
      • Obviousness
      • Written Description
      • Enablement
    • Anatomy of a U.S. Patent
      • Utility Patent
      • Design Patent
      • Plant Patent
    • Trademark Law
    • Copyright Law
    • Trade Secrets
    • Know How
    • Intangible Assets

Chambers Spotlight California 2025 Torrey Pines Law Group   Clio Reisman Award Torrey Pines Law Group COPYRIGHT © , TORREY PINES LAW GROUP, PC. ALL RIGHTS RESERVED. | LEGAL NOTICES | SITE MAP

Torrey Pines Law Group, PC serves technology innovators with protecting intellectual property, obtaining regulatory approvals and clearances, and making deals and closing technology transactions throughout the U.S., including in major technology hubs such as San Diego, San Francisco, Palo Alto, San Jose, Silicon Valley, Boston, Cambridge, Chicago, Minneapolis, Houston, Dallas, Atlanta, Denver, Seattle, Portland, Boulder, Orlando, the Research Triangle (Raleigh, Durham, and Chapel Hill), the Mid-Atlantic (New Jersey, New York, Philadelphia, Maryland, Virginia, and Washington, DC), Pittsburgh, Cleveland, Ann Arbor, and throughout Southern California in Los Angeles, Orange County, Irvine, Torrey Pines, Sorrento Valley, and La Jolla.

We have experience with international intellectual property, regulatory and transactional matters pending in Beijing, Shanghai, Shenzhen, and Guangzhou China; Tokyo, Japan; Berlin, Munich and Frankfurt Germany; Tel Aviv Israel; Mumbai, Bengaluru, and New Delhi India; London and Edinburgh United Kingdom; Vancouver, Toronto, Calgary and Montreal Canada; Dublin, Ireland; Cape Town, South Africa; Mexico City and Tijuana Mexico; Brussels, Belgium; Copenhagen, Denmark; Paris, France; Madrid and Barcelona Spain; Moscow, Russia; Santiago, Chile; Montevideo, Uruguay; Buenos Aires, Argentina; Sao Paulo and Rio de Janeiro Brazil; Seoul, South Korea; Taipei, Taiwan; Hong Kong; Hanoi, Vietnam; Bangkok, Thailand; Kuala Lumpur, Malaysia; Milan, Italy; Singapore; Sydney, Melbourne, Perth and Adelaide Australia; Auckland, New Zealand; Oslo, Norway; Stockholm, Sweden; Helsinki, Finland; Kiev, Ukraine; Budapest, Hungary; Vienna, Austria; Prague, Czechia; Geneva and Lausanne Switzerland; Bahrain; Doha, Qatar; Abu Dhabi and Dubai UAE; and Jeddah, Saudi Arabia.

San Diego Patent Written Description Law Firm - Orange County Patent Written Description Counsel - Los Angeles Patent Written Description Opinions - International Patent Written Description Law